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A new in vitro assay was developed to detect human epidermal growth factor receptor 2 (HER2) protein,
based on aﬃnity dissociation of carbon nanotube (CNT)-wrapped anti-HER2 ssDNA aptamers. First, we
selected an anti-HER2 ssDNA aptamer (H2) using an in vitro serial evolution of ligands by an exponential
enrichment (SELEX) process. Then the ﬂuorescently labelled H2 ssDNAs were tightly packed on CNTs
that had previously been coupled with magnetic microbeads (MBs), forming MB–CNT–H2 hybrids. The
loading capacity of these MB–CNTs heterostructures (2.8  108) was determined to be 0.025 to 3.125
mM of H2. HER2 protein-induced H2 dissociation occurred from MB–CNT–H2 hybrids, which was
speciﬁcally induced by the target HER2 protein, with a dissociation constant (Kd) of 270 nM. The
stoichiometric aﬃnity dissociation ratio with respect to H2-to-HER2 protein was shown to be
approximately 1 : 1. Our results demonstrated that the developed assay can be an eﬀective approach in
detecting native forms of disease biomarkers in free solutions or in biological samples, for accurate
diagnosis.1. Introduction
Nanomaterials are now used in a wide spectrum of applications
in the biomedical eld. They have been eﬀectively utilized to
deliver biologically active cargo to the sites of interest for
purposes of cancer diagnosis and therapy.1–3 Various nano-
structured materials such as carbon nanotubes (CNTs),4 poly-
meric nanoconjugates,5,6 and nanoparticles7,8 have been
explored, especially in cancer therapy.9 The unique physico-
chemical properties of CNTs have been exploited as popular
tools in cancer diagnosis and therapy.10 They are considered
one of the most promising nanomaterials, with the capability of
both detecting cancerous cells and delivering small therapeutic
molecules.10 In addition, CNTs can eﬀectively shuttle various
bio-molecules into cells, including drugs,3,11 peptides,12
proteins,13 plasmid DNA,14 small interfering RNA,15 and
aptamers,16 via endocytosis.17 Therefore, it is imperative to
develop new methods utilizing the unique physicochemical
properties of CNTs in biomedical applications, including therch and Application Center, Orta Mah,
banciuniv.edu; Fax: +90 216 483 9885;
, JSS College of Pharmacy, SS Nagara
(ESI) available: Fig. S1 illustrating the
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ed to bind against HER2 protein aer
01665c
hemistry 2015detection of cancer biomarkers at the early stages with high
specicity and selectivity.
Tumor-targeted therapies require ligands that can bind to
cancer cells where aptamers can represent an alternative ther-
apeutic modality. These molecules are small, single-stranded
DNA or RNA in nature.18 Aptamers have great prospects in
therapeutic applications, especially in cancer treatment. For
example, AS1411, a nucleolin-specic truncated version of an
aptamer called GRO29A, is currently in advanced clinical
trials.19 Other therapeutic aptamers that have been tested for
antiviral, anticoagulation, anti-inammatory and anti-
angiogenic properties are already in clinical trials.20 Macugen is
the rst clinically approved aptamer made of ssRNA molecules
that eﬀectively inhibits macular degeneration.21 With the aim of
creating a more eﬀective tool for cancer diagnosis, we consid-
ered human epidermal growth factor receptor 2 (HER2) as a
target cancer marker protein.
HER2, also known as ErbB2, Neu, CD340 or P185 is a
transmembrane tyrosine kinase receptor and a member of the
epidermal growth factor receptor (EGFR or ErbB) family. Over-
expression of 20–30% HER2 is shown to be associated with
aggressive breast cancer cases.22 The overexpression of HER2
levels is also linked to other cancers, including ovarian, lung,
gastric, and oral.22,23 Therefore, it is imperative to monitor HER2
levels to enable early cancer diagnosis. Existing methods for
detecting HER2 are based on expensive biopsies followed by
conducting immunohistochemistry (IHC) and uorescence in
situ hybridization (FISH) techniques for detecting HER2 protein
levels.24,25 Synthetic tyrosine kinase inhibitors such as erlotinibAnalyst, 2015, 140, 243–249 | 243
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View Article Onlineand getinib as well as monoclonal antibodies, such as cetux-
imab and trastuzumab, have been developed to inhibit patho-
logical signaling or to recruit the immune system against cancer
cells.26,27
Targeting HER2 with low molecular weight kinase inhibitors
has established this family of receptors as an eﬀective target for
novel drugs. Thus, therapeutic use of anti-HER2 aptamers is a
promising alternative to monoclonal antibodies and kinase
inhibitors for clinical applications, mainly because of their
relatively low production cost as well as low batch-to-batch
variability.27 Anti-HER2 aptamers have been increasingly
developed that have high aﬃnity and specicity to HER2, and
these have been shown to inhibit proliferation of cultured
cancer cells.28–32Nevertheless, there is still a need for developing
new aptamer variants against cancer biomarkers that can
potentially serve as inhibitory agents for cancer diseases.
Determination of increased HER2 protein levels in human
serum is an alternative approach of utilizing such aptamers in
combination with CNT structures so as to enable the treatment
of cancer in its early stages and the eﬀective prevention of
traumatic events.
In this paper, we rst hypothesize an in vitro delivery system
which utilizes CNTs that carry anti-HER2 aptamers and release
specically when the target HER2 protein is supplied in the
synthetic medium. This hypothesis was experimentally tested
by rst selecting a specic anti-HER2 aptamer using the SELEX
process. The selected anti-HER2 aptamer was packed around
CNTs by physical wrappings that had in turn been previously
coupled with MBs. These heterogeneous structures were
employed to demonstrate the specic dissociation of anti-HER2
aptamers, which was induced by their strong aﬃnity toward
HER2 protein. This feature is most desirable for a ligand
molecule to qualify for potential targeted drug-delivery appli-
cation under in vivo conditions.
2. Experimental
2.1 In vitro selection of ssDNA aptamers that bind HER2
2.1.1 Preparation of HER2 protein-coated magnetic beads.
Pure and carrier-free recombinant HER2 (ErbB2) protein (R&D
Systems®) was rst conjugated with surface-activated magnetic
Dynabeads® M-270 Carboxylic Acid (Invitrogen, USA) using a
carbodiimide coupling method as described by the manufac-
turer. The HER2 protein-coated beads were magnetically sepa-
rated and washed thrice with 100 mL of PBS, pH 8 containing
0.05% Tween 80 and nally resuspended in 100 mL of PBS, pH
7.4 containing 0.1% BSA and stored at 4 C. Thus obtained, the
HER2 protein-coated beads were utilized for in vitro selection of
ssDNA aptamers using the SELEX process.
2.1.2 Negative selection. Negative selection was carried out
as a prerequisite step to eliminate the non-specic oligos from
the initial random ssDNA pool prior to beginning the anti-HER2
aptamer selection process. For this, 1015 diverse ssDNAs
molecules (random library) with the sequence 50-
GGGCCGTTCGAACACGAGCATG(N)40GGACAGTACTCAGGTC
ATCCTAGG-3' (pool-1) were incubated with each aliquot of
2  107 beads coated with (i) ethanolamine and (ii) BSA,244 | Analyst, 2015, 140, 243–249followed by (iii) naked beads, to eliminate the non-binders from
the main ssDNA pool. The residual ssDNA pool (pool-2) was
resuspended in 1 : 10 diluted human serum (male; blood type,
AB+; PANTM Biotech GmbH) in 1 binding buﬀer (100 mM
NaCl, 20 mM Tris–HCl pH 7.6, 2 mM MgCl2, 5 mM KCl, 1 mM
CaCl2, 0.02% Tween 20) allowing removal of undesirable oligos,
and this mixture containing random, free ssDNA pool (pool 3)
was nally utilized for the SELEX process.
2.1.3 SELEX. It was essential to subject the random ssDNA
pool to thermal treatment in order to attain their most stable
conrmations before allowing these molecules to be incubated
with the target protein. Therefore, at the beginning of each
selection round, the initial ssDNAs were denatured at 90 C for
10 min and quickly cooled at 4 C for 15 min followed by
incubation for 7 min at room temperature (25 C). The pre-
treated ssDNA pool was later utilized for selection of anti-HER2
aptamers using SELEX, as per the method described previ-
ously.33 Details of the steps involved in the SELEX process are
schematically shown in (ESI) Fig. S1.†
The HER2 protein-bound sequences were eluted, puried
and amplied by symmetric/asymmetric PCR using the forward
primer, 50-uorescein-GGGCCGTTCGAACACGAGCATG-30 (F1)
and the reverse primer, 50-GGACAGTACTCAGGTCATCCTAGG-30
(R1). Amplied PCR product (dsDNA) carrying the aptamer
sequence was labelled uorescently during the PCR reaction,
and was extracted aer resolving on 2% agarose gel followed by
purication using a gel extraction kit (QIAquick, Qiagen).
Puried dsDNA was further resolved by denaturation poly-
acrylamide gel electrophoresis (PAGE, 12%), using 7 M urea
containing 20% formamide, and isolation of the target uo-
rescent ssDNAs by gel excision followed by extraction using a
PAGE gel extraction kit (Qiaex II). Obtained ssDNAs were
measured using a Nanodrop spectrophotometer (Thermo
Scientic) and applied as the isolated ssDNA fraction in the next
selection round, as the starting pool. The above process was
repeated for at least 12 cycles of selection, each comprising a
series of steps as illustrated in Fig. S1.† An optimized PCR
program was used to amplify the HER2-bound ssDNAs as
follows: initial 15 min denaturation at 95 C, 35–40 cycles of 30 s
denaturation at 94 C, 30 s annealing at 53 C and 30 s ampli-
cation at 72 C, respectively, with a nal extension step at 72 C
for 10min. The nal pool of selected aptamers was cloned using
a TOPO-TA cloning kit (Invitrogen) and sequenced. The
secondary structure prediction of the aptamer sequences was
evaluated using m-fold web server (utilizes free energy mini-
mizing algorithm) available at http://www.bioinfo.rpi.edu/
applications/mfold.34 As a result, 7 positive clones designated
as H1–H7 were obtained, from which one of the aptamers, H2,
was selected for further studies. All experimental methods
related to the cloning and screening of positive clones are
described in the ESI section.†2.2 In vitro assay for aﬃnity displacement/dissociation of
anti-HER2 aptamers
2.2.1 Fabrication of MB–CNTs heterostructures and
binding assays. Magnetic microbeads (Dynabeads®, M270This journal is © The Royal Society of Chemistry 2015
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View Article OnlineAmine, MBs) were covalently coupled with carboxyl-function-
alized multi-walled CNTs O.D.  L ¼ 10–20 nm  5–30 mm
(Arry®, Hong Kong). Stock CNTs (1 mg mL1) were dispersed in
0.1% Tween 20, and the suspension was homogenized by
ultrasonication using a probe sonicator (Bandelin, Germany),
and a well-dispersed and homogeneous CNT suspension was
added to the magnetic beads with intermittent agitation to
allow physical interaction of CNTs with the magnetic beads,
according to the method previously described.35 The thus-
formed magnetic microbeads coated with uniform layers of
CNTs were isolated by applying an external magnetic eld. The
magnetic nature of MBs allowed extensive washing of MB–CNTs
for the eﬀective removal of unattached CNTs and thereby
minimized the surfactant eﬀect. Aer extensive washing, the
inherent brown color of MBs turned black, indicating the strong
attachment of CNTs on the surface.35 SEM images were taken of
the beads for further conrmation of the homogeneous CNT
layer coating. To prevent attachment of surface CNTs present on
MB–CNTs, the MB–CNTs were suspended in a mild surfactant
solution (0.01% Tween 20), which facilitated the homogeneous
suspension of MB–CNTs. The thus-formed MB–CNT hetero-
structures were utilized for further studies.
2.2.2 Physical adsorption of anti-HER2 ssDNAs on MB–
CNTs heterostructures. A constant amount (2.8  108) of MB–
CNT heterostructures was incubated with varying ssDNA
concentrations in 1 binding buﬀer (BB). Here, the ssDNAs
used were 50 labelled with uorescein in order to trace the
uorescence levels (emission at 523 nm) in the reaction mixture
aer excitation at 470 nm. The reaction mixture was incubated
on a vortex mixer for 15 min at room temperature. The binding
capacity of MB–CNTs with ssDNAs was estimated by measuring
the uorescence (l523) in the supernatant solution using a
Nanodrop Fluorospectrometer (Nanodrop Technologies, Inc.,
USA). The MB–CNT–ssDNA hybrids were washed in a series of
steps until the supernatant showed no detectable uorescence
and nally stored at 4 C until use. The physical wrapping of
ssDNAs around CNTs was conrmed by Fourier transform
infrared spectroscopy (FTIR; Nicolet 6700). The ssDNA loading
capacity of MB–CNT heterostructures was calculated to be a
maximum of 3.125 mM ssDNA with 2.8  108 MB–CNTs.
Stability tests of MB–CNT–ssDNA hybrid structure were carried
out and the detailed steps are described in the ESI section.†
2.2.3 HER2 protein-dependent aﬃnity dissociation of anti-
HER2 aptamers from MB–CNT–ssDNA hybrid structures. Ten
identical aliquots, each carrying 4  107 MB–CNT–ssDNA
hybrid structures were suspended in 200 mL 1 BB. These
aliquots were divided into two pools, each with 5 aliquots, for
test and control groups. A constant 10 mL of 300 nM of HER2
protein prepared from stock 7.5 mg/200 mL in 1 BB was added
and incubated for binding against a series of diﬀerent
concentrations of ssDNA wrapped on MB–CNTs (MB–CNT–
ssDNA hybrids). The binding kinetics and HER2 protein-
induced ssDNA dissociation by unwinding from hybrid struc-
tures (aﬃnity separation) were studied. The beads were
magnetically separated and the uorescence was measured in
the supernatant, which corresponded to the amount of ssDNAs
dissociated from MB–CNT–ssDNA hybrids. For controls,This journal is © The Royal Society of Chemistry 2015instead of HER2 protein, BSA was used as a non-specic
protein. The above process was repeated until reaching a satu-
ration point.
2.2.4 Kinetics of anti-HER2 aptamer (MB–CNT–ssDNAs
hybrids) interaction with HER2 protein and dissociation
constant (Kd). First, a standard plot of known concentrations of
uorescein-labelled H2 ssDNA versus uorescence emission at
523 nm was established. A series of controlled numbers of MB–
CNT–ssDNA heterostructures corresponding to 0.025–3.125 mM
H2 ssDNAs was incubated with a constant 300 nMHER2 protein
in 1 BB solution for 15 min. For respective controls, BSA was
used as a non-specic protein. Relative uorescence units
(RFUs) directly obtained by uorospectrometer (which,
according to the manufacturer, is derived from the relationship
between 2–4 wavelengths) was measured from the aqueous
phase and the values converted to H2 ssDNA concentration
(aﬃnity dissociated) and plotted against the initial ssDNA
concentrations added. The data points were tted using non-
linear regression analysis, and the dissociation constant was
calculated with the help of the SigmaPlot v12 program using
one-site saturation, under ligand-binding mode, which utilized
the following equation:
y ¼ Bmax  free ssDNA/Kd + free ssDNA (1)
where y is degree of saturation, Bmax is the number of maximum
binding sites (here one-site binding option was employed), and
Kd is the dissociation constant.363. Results and discussion
3.1 In vitro selection of anti-HER2 aptamers
Anti-HER2 aptamers were selected in vitro through directed
selection by combinatorial screening of random library of1015
ssDNA using the SELEX technique. As a result, seven aptamer
candidates were evolved that bound to HER2 protein in a
complex human serum medium. The sequences of the seven
selected aptamers (H1–H7) are listed in Table S1.† The binding
preference of an aptamer is important for its application as a
targeting ligand. An ideal tumor-targeting aptamer should bind
to the target molecule with minimal binding to other proteins.
Here, we found that the H2 sequence evolved multiple times
within the window of <50–60 nucleotides from the SELEX
process compared with the other aptamer candidates, indi-
cating its strong preference towards binding to HER2 protein.
Since albumin is themost abundant protein in blood, we spiked
HER2 protein in 1 : 10 diluted human serum as a background
component for in vitro selection and binding studies. The anti-
HER2 aptamer (H2) chosen in this study also had a most stable
conrmation due to its double strandedness, because of its
more negative DG value, aer H1, from among the seven
aptamer candidates.34 The calculated DG with the following H2
sequence—50-GGGCCGTCGAACACGAGCATGGTGCGTGGACCT
AGGATGACCTGAGTACTGTCC-30 (M.W.¼ 16.72kDa)—was6.69kcal
mole1. This result indicated that the single strandedness of the
aptamer was able to spontaneously transform into its most
stable double stranded structure (Fig. 1). The predictedAnalyst, 2015, 140, 243–249 | 245
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View Article Onlinesecondary structure of H2 showed two stem-loops and the
random sequence was found to be located in its major stem-
loop structure, which was predicted to be the binding site for
HER2 protein (Fig. 1).Scheme 1 Schematic diagram showing sequential steps involved in in
vitro method employed for HER2-speciﬁc targeted release/dissocia-
tion of H2 fromMB–CNT–H2 cargos. Note that the graphics of beads,
ssDNA or proteins shown in the scheme do not reﬂect their actual size
or dimensions.3.2 In vitro aﬃnity dissociation of anti-HER2 aptamers
A new assay scheme was designed for testing in vitro HER2-
induced displacement or delivery of the anti-HER2 aptamer
(H2), in order to determine its stoichiometric binding or release
with respect to the H2-to-HER2 protein ratio. Interaction of DNA
and CNTs facilitates formation of supramolecular complexes37
and such interactions have been shown to adhere tightly, and to
form a uniform and stable lm that has been exploited for
useful applications.38 Here, CNTs were employed as cargos
(matrix) for carrying H2 ssDNAs that were coated on MBs so as
to form heterostructures for testing HER2 target protein-
induced displacement (aﬃnity dissociation) in the medium
(Scheme 1).
A heterogenous matrix made of CNTs decorated on MBs was
conrmed by SEM examination. Fig. 2a and b shows SEM
images of MBs before and aer uniform layer coating with
CNTs. A small increase in the size of dynabeads was observed
aer coating with CNTs, as seen in Fig. 2b. The H2 ssDNAs were
then allowed to tightly pack by physical wrapping on CNTs as
described in the Experimental section. Binding of uorescein-
labelled H2 on MB–CNTs was examined by measuring the
uorescence intensity at 523 nm that showed diminishing
uorescence in the reaction supernatant as a result of strong
H2–CNT interactions compared with the control. The dimin-
ishing of uorescence can be attributed to strong physical
wrapping of ssDNAs on CNTs present on MBs. Further, wrap-
ping of ssDNAs on CNT structures was conrmed by FTIR
spectra (Fig. S2†). The extent of H2 adsorption or loading
capacity with 2.8  108 MB–CNTs was determined to be in theFig. 1 Secondary structure of anti-HER2 (H2) aptamer predicted using
a free-energy minimizing algorithm, m-fold web server. The high-
lighted random region is predicted to be the HER2 protein-binding
sequence.
246 | Analyst, 2015, 140, 243–249range 0.025–3.125 mM H2 until reaching a saturation point
(Fig. 2c–f).
3.3 Stability of MB–CNT–H2 hybrid structures
MB–CNT–H2 hybrid structures were subjected to stability tests
by thermal and chemical denaturation. The released uores-
cence intensities at 523 nm were measured for dissociation of
CNT-wrapped ssDNAs at varying temperatures from 4 to 94 C
for 1 h. Fluorescence emission proles of H2 released fromMB–
CNT–ssDNA hybrids against varying temperatures with time
showed that no signicant unwrapping of ssDNAs occured from
CNT–ssDNAs hybrid structures at temperatures 4–94 C (ESI,†
Fig. 3). However, a partial dissociation of ssDNAs from hybrid
structures did occur but only with 0.1% SDS, probably due to
surfactant-induced unfolding or unwrapping of ssDNAs. It is
clear from the above results that the ssDNAs were tightly
wrapped on MB–CNTs, which required a strong surfactive agent
such as SDS to dissociate them from CNTs.
3.4 In vitroHER2 protein-induced aﬃnity release of H2 from
MB–CNT–H2 (cargos)
Competitive stoichiometric dissociation of H2 ssDNAs was
initially postulated to occur by the inuence of HER2 protein in
the reaction mixture as schematically illustrated in Scheme 1.
This hypothesis was tested by allowing interaction of HER2
protein with MB–CNT–ssDNA hybrid structures (cargos).
Dissociation because of the strong binding aﬃnity of H2 toward
HER2 protein was therefore determined using a series of MB–
CNT–ssDNA hybrid structures (1–5  107) loaded with 0.05–0.3
mM H2 ssDNAs. These hybrid structures were incubated with aThis journal is © The Royal Society of Chemistry 2015
Fig. 2 SEM images of (a) bare MBs and (b) fabricated MB–CNT heterostructures. The MB–CNTs (2  108) were loaded with ﬂuorescein-labelled
H2 ssDNA at diﬀerent concentrations, such as (c) 0.025 mM, (d) 0.125 mM, (e) 0.625 mM, and (f) 3.125 mM, and the released ﬂuorescence (after
excitation at 470 nm) in the reaction supernatant before (blue) and after incubation (red) with MB–CNTs are shown in (c) to (f).
Fig. 3 Stability of MB–CNT–H2 hybrid structure suspended in binding
buﬀer (BB) after thermal and surfactant treatments. Relative ﬂuores-
cence units (RFUs) measured after the MB–CNT–ssDNAs suspension
incubated for 1 h at diﬀerent temperatures on a surfactant, as shown in
the legend. The ﬁgure shows that non-speciﬁc dissociation of H2 in
the aqueous phase of the reaction mixture occured only with 0.1%
SDS.
Fig. 4 Binding of HER2 protein with increasing concentrations of free
ssDNA (H2) aptamers that were aﬃnity-dissociated from the tightly
packed MB–CNT–ssDNA hybrid structures. Saturation curve was
obtained after plotting the concentration of aﬃnity-dissociated H2
ssDNA against constant HER2 protein (300 nM). The inset shows a
linear ﬁt of measured RFU values, corresponding to the linear range of
HER2 protein concentrations.
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View Article Onlineconstant 300 nM pure and carrier-free form of HER2 protein.
HER2 protein-induced dissociation of H2 was evidenced from
MB–CNT–ssDNA hybrids, which was dose-dependent and
accompanied by an increase in uorescence intensity (Fig. 4).
The reaction supernatant contained the H2 ssDNA–HER2
protein complex; this exhibited a uorescence property because
of the uorescein dye at its 50-end that did not quench, as
opposed to that seen with QD-conjugated H2 in dot-blot assays.This journal is © The Royal Society of Chemistry 2015As the number of MB–CNT–ssDNA conjugates increased, H2
binding with HER2 increased as well, until reaching a satura-
tion point (Fig. 4).
The H2 ssDNA corresponding to the RFU values were tted
using non-linear regression analysis, and the dissociation
constant (Kd) according to one-site binding was calculated to be
270 nM with 300 nM HER2 protein present in the reaction
mixture. This result indicated that an approximate 1 : 1 stoi-
chiometric molecular binding occurred with ssDNA-to-HER2Analyst, 2015, 140, 243–249 | 247
Fig. 5 Aﬃnity dissociation of H2 from constant MB–CNT–H2 hybrid
structures incubated with the same amount of BSA and HER2 proteins
(300 nM). The H2 aptamer was dissociated only in the presence of
HER2 protein, but not in the presence of BSA, a non-speciﬁc protein.
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View Article Onlineprotein. Similar 1 : 1 stoichiometric binding with EGF and
EGFR was reported by another research group.39 Further, a
dynamic detection range of 50–250 nM was established using
the measured RFU values corresponding to HER2 protein that
exhibited a limit of detection of 38 nM (47.5 ng/10 mL sample
volume) of HER2 protein (Fig. 4). This range is comparable to
previously reported studies.40
The specic ability of H2 binding with HER2 protein was
conrmed by specicity tests using a constant number of MB–
CNT–ssDNAs incubated against each protein (HER2/BSA) at
equimolar concentrations that showed no non-specic
displacement of H2 occurred against BSA protein (Fig. 5). The
methods employed in this study therefore hold an advantage of
H2 ssDNA binding with HER2 protein in its native and free
forms, which is most desirable in clinical diagnosis, thus
making the developed assay a simple and rapid tool for specic
and accurate biomarker detection.4. Conclusions
The present study provides a unique strategy to target HER2
protein for the detection of protein biomarkers in the context of
cancer diagnosis or therapy using anti-HER2 aptamers. HER2 is
overexpressed in many tumors, providing binding sites that can
be directly accessible to aptamers from circulating blood. The
high aﬃnity and specicity of aptamers with HER2 protein from
tumor cells are useful targets for the sensitive and accurate
diagnosis of various types of cancers. In this study, H2 anti-
HER2 aptamer was selected in vitro and employed on the basis
of its ability to eﬀectively bind to HER2 protein in the complex
human serum environment. This method did not require any
additional chemical reagents, enabling detection of HER2
protein in its native forms in human serum and thus making it
a highly preferred method in clinical diagnosis.
Use of CNTs for targeted delivery is a signicant develop-
ment in the eld of therapeutic nanomedicine or cancer diag-
nosis for targeting cells that abundantly express HER2 protein.
The strategy of target-induced aﬃnity dissociation is a prom-
ising alternative to existing technologies for cancer diagnosis or248 | Analyst, 2015, 140, 243–249therapy. Therefore, a unique in vitro method was developed
aimed at testing MB–CNTs as cargos of H2 ssDNAs. These car-
gos were loaded with calculated amounts of uorescently
labelled anti-HER2 aptamer (H2) and successfully tested for its
ability for programmable release, which was inuenced by the
presence of abundant HER2 protein in the medium. This
strategy can potentially be explored in in vivo models for anti-
HER2 aptamers as inhibitory drug-delivery systems. Our study
demonstrated that the aptamer-mediated cancer diagnosis
could be explored further as anti-HER2 therapy or detection of
HER2 levels in serum.Acknowledgements
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